EDSA (Edesa Biotech) Moat Score: 2/10 (As of Jul. 02, 2026)


EDSA Edesa Biotech Inc EDSA
26 GF Score
Price $7.45
! 2 Warning Signs
View Full Analysis

What is Edesa Biotech Moat Score?

Edesa Biotech EDSA -3.23% 26 Moat Score is 2 as of Jul. 02, 2026. GuruFocus rates EDSA with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 1,400 Biotechnology companies, Edesa Biotech ranks better than 58.07% on this metric.

Edesa Biotech has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Edesa Biotech has No Moat: Edesa Biotech Inc lacks significant market leadership and has limited intellectual property. The biotech industry is highly competitive with low switching costs and minimal brand strength. The company does not exhibit durable cost advantages or significant regulatory barriers, resulting in a very weak competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Edesa Biotech might have No Moat - Very weak/transient advantages.

Edesa Biotech  (NAS:EDSA) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Edesa Biotech Moat Score Related Terms

EDSA vs ACET, HRTX, ENTX: Moat Score Comparison

For the Biotechnology subindustry, Edesa Biotech's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Edesa Biotech Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Edesa Biotech's Moat Score distribution charts can be found below:

* The bar in red indicates where Edesa Biotech's Moat Score falls into.


EDSA
26GF Score
Edesa Biotech Inc EDSA
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Edesa Biotech (EDSA) has a Moat Score of 2 as of Jul. 02, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Edesa Biotech ranks #587 out of 1400 companies in the Biotechnology industry, placing it in the top 41.9%.
Is Edesa Biotech's Moat Score too high?
Edesa Biotech's current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Edesa Biotech's value of 2 is 0% at this industry median. Based on the distribution chart, Edesa Biotech ranks #587 out of 1400 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Edesa Biotech has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Edesa Biotech's Moat Score compare to ACET and HRTX?
According to the Biotechnology industry distribution chart, Edesa Biotech ranks #587 out of 1400 companies for Moat Score. This puts Edesa Biotech in the upper half of its industry. The industry median Moat Score is 2.00. Edesa Biotech's value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Edesa Biotech's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edesa Biotech's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edesa Biotech stock overvalued right now?
Edesa Biotech (EDSA) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Edesa Biotech's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Edesa Biotech (EDSA), the current Moat Score is 2 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Edesa Biotech Business Description

Address 100 Spy Court, Markham, ON, CAN, L3R 5H6
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
26GF Score

Get the complete analysis for EDSA

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.45
Price